Malaysia is on the brink of a significant healthcare improvement as it prepares to receive the antiviral drug Tecovirimat (TPOXX) and the MVA-BN vaccine for mpox. These essential medical supplies will be delivered via the Covid-19 Asean Response Fund, announced Health Minister Datuk Seri Dzulkefly Ahmad in a series of posts on X, formerly known as Twitter.

Tecovirimat, a potent antiviral, will be utilised primarily for treating mpox, especially in patients grappling with severe infections or those with compromised immune systems. This approach underscores the government’s commitment to safeguarding its most vulnerable populations. The Health Minister elaborated on the vaccination strategy, stating that the MVA-BN mpox vaccine would be administered selectively, based on thorough examination and evaluation by medical experts. General vaccinations are not on the agenda.

Dzulkefly highlighted that the MVA-BN vaccine would be reserved for high-risk groups. This includes healthcare workers and close contacts of confirmed mpox cases, ensuring that those on the frontline and those directly exposed receive priority protection.

The World Health Organisation has once again declared an outbreak of mpox as a global health emergency. This marks the second time in two years that this viral infection, which spreads through close contact, has warranted such a status.

In an effort to curb the spread of mpox, Malaysia’s Ministry of Health (MoH), in collaboration with Malaysia Airport Holdings Bhd, has intensified screening procedures at Kuala Lumpur International Airport (KLIA) Terminal 1 since August 29. Every traveller arriving on international flights will now be subject to thermal scanning to detect potential mpox infections. This measure aims to nip any potential outbreaks in the bud by identifying infected individuals early.

The government has also taken proactive steps by activating a special operations room at the National Crisis Preparedness and Response Centre (CPRC) since August 16. This centre is tasked with monitoring and preventing the spread of mpox in coordination with other Asean countries. It demonstrates a robust regional approach to tackling this health threat.

The MoH has reported that nearly 2.64 million travellers have been screened at the country’s international entry points since August 16. Remarkably, no suspected mpox cases have been detected among these travellers, reflecting the effectiveness of the enhanced screening measures.

The introduction of Tecovirimat and the targeted use of the MVA-BN vaccine represent a strategic response to a growing health concern. Tecovirimat, also known as TPOXX, is an antiviral medication that inhibits the activity of the orthopoxvirus family, which includes mpox. It was initially developed for smallpox but has shown efficacy against other orthopoxviruses as well. The selective administration of the MVA-BN vaccine aligns with current medical guidelines, which recommend vaccination for those at high risk rather than mass immunisation.

Healthcare workers are at the forefront of this battle against mpox and are among those most at risk of exposure. The decision to prioritise them for vaccination reflects an understanding of their critical role in managing and containing infectious diseases. Close contacts of confirmed cases are also high on the priority list, given their increased likelihood of contracting the virus.

The World Health Organisation’s declaration of mpox as a global health emergency underscores the severity of this outbreak. Mpox is characterised by symptoms similar to smallpox but generally less severe. It spreads through close contact with an infected person or contaminated materials, making it a highly transmissible virus.

The enhanced screening procedures at KLIA Terminal 1 are part of a broader strategy to prevent mpox from entering and spreading within Malaysia. Thermal scanners are an effective tool for identifying individuals with fever, one of the primary symptoms of mpox. By screening all international travellers, authorities hope to identify and isolate potential cases before they can transmit the virus to others.

The activation of the special operations room at the CPRC is another critical component of Malaysia’s response. This operations room serves as a command centre for coordinating efforts to monitor and prevent mpox. It works in tandem with other Asean countries to share information and strategies, reflecting a collaborative regional approach to this health threat.

The MoH’s report on traveller screenings provides a reassuring update on the current situation. The fact that no suspected cases have been detected among nearly 2.64 million screened travellers suggests that the measures in place are working effectively. However, continuous vigilance is essential to maintain this status.

Malaysia’s proactive measures in response to the mpox outbreak demonstrate a comprehensive approach to public health. The introduction of Tecovirimat and the targeted use of the MVA-BN vaccine reflect a strategic plan to protect high-risk groups and prevent widespread transmission. Enhanced screening procedures at international entry points and the activation of a special operations room underscore the seriousness with which Malaysia is addressing this global health emergency. The collaborative efforts with Asean countries highlight the importance of regional cooperation in tackling infectious diseases.

Malaysia’s readiness to tackle this health challenge head-on showcases its commitment to protecting its population and maintaining public health security. With vigilant monitoring and strategic interventions, Malaysia aims to keep mpox at bay and ensure the safety and well-being of its citizens.